{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:53:24Z","timestamp":1792508004600,"version":"4.5.0"},"reference-count":27,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Cosmetic Dermatology"],"published-print":{"date-parts":[[2024,2]]},"abstract":"Abstract<\/jats:title>\n \n Purpose<\/jats:title>\n Topical minoxidil (MNX) 2%\u20135% and oral finasteride (F) 1\u2009mg\/day are the only two pharmacological treatments authorized for androgenetic alopecia (AGA). Recently, a 2.2\u2009mg\/mL topical formulation of F was developed to minimize the systemic adverse effects associated with the oral formula. MNX and F act through different mechanisms; therefore, their association could improve clinical efficacy. To evaluate the efficacy of the association of 5% MNX and 0.25% topical F compared to their use in monotherapy, a 6\u2010month, prospective, randomized, assessor\u2010blinded trial was conducted.<\/jats:p>\n <\/jats:sec>\n \n Patients and Methods<\/jats:title>\n \n Forty\u2010two males, mean age 24\u2009\u00b1\u20093\u2009years, with AGA (I\u2013VII of Norwood\u2010Hamilton Grading Scale), treatment naive or free from any therapy for at least 6\u2009months, were enrolled and randomly assigned to three arm treatment groups (2:1:1): group A (\n n<\/jats:italic>\n \u2009=\u200919, the subjects applied 5% MNX in the morning and F spray in the evening), group B (\n n<\/jats:italic>\n \u2009=\u200912, the subjects applied F spray in the evening), and group C (\n n<\/jats:italic>\n \u2009=\u200911, the subjects applied 5% MNX twice daily). The efficacy of treatments was evaluated at baseline and after 3 and 6\u2009months using a global photography score (GPAS; from \u22123 to +3) and trichoscopy evaluation and assessed by an investigator unaware of treatment allocation. At baseline and after treatments, the serum levels of follicle\u2010stimulating hormone (FSH), luteinizing hormone (LH), dehydroepiandrosterone sulfate (DHEA\u2010S), and testosterone were also evaluated.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n All treatments resulted in an increase in hair density compared to baseline. However, this improvement was significant only for group A (MNX\u2009+\u2009F), both at three (+56 density\/cm\n 2<\/jats:sup>\n ,\n p<\/jats:italic>\n \u2009<\u20090.05) and six (+81 density\/cm\n 2<\/jats:sup>\n ,\n p<\/jats:italic>\n \u2009<\u20090.001) months. The mean change from baseline in hair density was higher for group A compared to other groups and statistically different compared to group B (F) (\n p<\/jats:italic>\n \u2009<\u20090.01), both after 3 and 6\u2009months. Group A showed a global photographic assessment score (GPAS) significantly higher compared to group B (\n p<\/jats:italic>\n \u2009<\u20090.001) and group C (\n p<\/jats:italic>\n \u2009<\u20090.05) both at 3 and 6\u2009months (2.0\u2009\u00b1\u20090.7 vs. 0.6\u2009\u00b1\u20090.8 and 1.3\u2009\u00b1\u20090.6; respectively). A significantly greater percentage of subjects in Group A achieved a GPAS score of \u22652 in comparison with Groups B and C both after 3 and 6\u2009months (79% vs. 8% and 41%, respectively). No significant differences were observed in mean hair diameter and hormonal levels between the three groups. Good tolerability was observed in all treated groups.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n The association of 5% MNX lotion and 0.25% F in spray formulation in patients with AGA showed a significantly higher clinical and instrumental efficacy compared to the monotherapies, with comparable tolerability and safety profile.<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/jocd.15953","type":"journal-article","created":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T01:42:38Z","timestamp":1696556558000},"page":"502-509","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Efficacy of the association of topical minoxidil and topical finasteride compared to their use in monotherapy in men with androgenetic alopecia: A prospective, randomized, controlled, assessor blinded, 3\u2010arm, pilot trial"],"prefix":"10.1111","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7442-3423","authenticated-orcid":false,"given":"Alfredo","family":"Rossi","sequence":"first","affiliation":[{"name":"Dermatologic Clinic Policlinico Umberto 1 Sapienza University of Rome Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6568-3389","authenticated-orcid":false,"given":"Gemma","family":"Caro","sequence":"additional","affiliation":[{"name":"Dermatologic Clinic Policlinico Umberto 1 Sapienza University of Rome Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,10,5]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.02.054"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2012.10.008"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-017-1280-y"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S214907"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.23736\/S0392-0488.20.06554-2"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2011.01.013"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12390"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.0570111"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17738"},{"issue":"1","key":"e_1_2_12_11_1","first-page":"129","article-title":"Long\u2010term (5\u2010year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia","volume":"12","author":"Kaufman KD","year":"2002","journal-title":"Eur J Dermatol"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2008.0436"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2011.01441.x"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.15761\/crt.1000273"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14719"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12246"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2002.tb00314.x"},{"key":"e_1_2_12_18_1","first-page":"1312","article-title":"Efficacy and safety of 3% minoxidil versus combined 3% minoxidil \/ 01% finasteride in male pattern hair loss: a randomized, double\u2010blind, comparative study","volume":"95","author":"Tanglertsampan C","year":"2012","journal-title":"J Med Assoc Thail"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.4172\/2155-9554.1000253"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15171"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.5743"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14624"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1782324"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.45220"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546639709160517"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.05785.x"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.119104"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.29011\/2575-8268.100199"}],"container-title":["Journal of Cosmetic Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jocd.15953","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T02:15:51Z","timestamp":1706235351000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jocd.15953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,5]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1111\/jocd.15953"],"URL":"https:\/\/doi.org\/10.1111\/jocd.15953","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742817962.793601214","asserted-by":"object"}]},"ISSN":["1473-2130","1473-2165"],"issn-type":[{"value":"1473-2130","type":"print"},{"value":"1473-2165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,5]]},"assertion":[{"value":"2023-03-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}